DETECTING NEONATAL SEPSIS USING MOLECULAR TECHNIQUES

描述：(改编自《调查者摘要》)：约150,000 到500,000名胎龄超过34周的婴儿进入NICU 每年有系统性感染风险的人。这些婴儿都收到了 全身性抗生素治疗。然而，这些婴儿中的绝大多数是 没有被感染，但有其他医学上次要的症状 条件。目前评估新生儿败血症的护理标准是 血液培养，缺乏敏感性，在此之前不能提供信息 至少24到46小时。因此，长期使用抗生素治疗。 在许多新生儿中，如果更快的测试排除了这一点，这一时间可能会缩短 有脓毒症。此应用程序建议调查两个潜在的 基于聚合酶链式反应的细菌16S核糖体检测方法 DNA和基于ELISA法的防御素检测，以确定它们作为 新生儿全身性感染的早期预测指标。

DESCRIPTION: (Adapted from the Investigator's Abstract): Approximately 150,000 to 500,000 infants greater than 34 weeks gestational age are admitted to NICUs annually who are at risk for systemic infection. These infants all receive systemic antibiotic therapy. However, the vast majority of these infants are not infected, but rather have symptoms that are secondary to other medical conditions. The current standard of care for evaluating neonatal sepsis is blood culturing, which lacks sensitivity and is not informative prior to at least 24 to 46 hours. As a result, there is prolonged use of antibiotic therapy in many newborns that could be shortened if a more rapid test to rule out sepsis was available. This application proposes to investigate two potential tests, a PCR-based amplification assay for detecting bacterial 16S ribosomal DNA and an ELISA-based assay for defensins, to determine their usefulness as early predictors of systemic neonatal infection.